• Users Online: 736
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
CASE REPORT
Year : 2018  |  Volume : 7  |  Issue : 1  |  Page : 88-91

CYP2C9*1*2 and VKORC1-1639 AA Polymorphisms Correlation with Warfarin Dose Requirement: A Case Report


Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Correspondence Address:
Kamran Mansouri
Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

CYP2C9 and VKORC1-1639 G>A genes as the genetic factors significantly influence the warfarin dose requirement in individuals. The patients with genetic variations in CYP2C9 and VKORC1 are at increased risk of adverse warfarin-related events. A young patient with atrial septal defect being highly sensitive to normal daily dose of warfarin was subjected to the study. The patient consented to genetic testing. Furthermore, DNA was isolated and PCR-RFLP performed. The patient required low warfarin dose of 11 mg/week to achieve the target international normalized ratio (INR). Genetic testing revealed that the patient carried VKORC1-1639 AA and CYP2C9*1*2 genotypes. Our findings reaffirm the significance of pharmacogenetic analysis prior to the warfarin therapy to achieve an efficient treatment and the least side/adverse drug effects.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed111    
    Printed23    
    Emailed0    
    PDF Downloaded35    
    Comments [Add]    

Recommend this journal